MagForce Nanotechnologies AG was selected from among over 1,500 entrants by a 17-person panel of judges chaired by Prof. Martin Roth, Director General of the Dresden State Art Collections, and Prof. Michael Hüther, Director of the Cologne Institute for Economic Research

This prospective phase I study of patients with inoperable pancreatic carcinoma is intended to show whether the use of nano-cancer therapy for this type of tumor is possible and whether the target temperatures can be reached with sufficient homogeneity and over a sufficient area

In preparation for a planned exchange listing, MagForce Nanotechnologies AG has successfully completed a capital increase with net proceeds in the single-digit millions of euros

The new members are Dr. Walter Rust, an attorney and notary in Berlin; Dr. Peter Heinrich, co-founder and chairman of the management board of MediGene AG; and Professor Wolfgang M. Heckl, general director of the Deutsches Museum, the world-famous museum of science and technology in Munich

This addition at the senior management level takes into account the company’s positive growth and the expected commercialization of nano-cancer therapy

The study in question is a prospective, multicentric study on increasing the effectiveness of LDR brachytherapy (seed implantation) in prostate cancer with intermediate risk. The primary aim of the study is to improve local tumor control (PSA control) and thus to increase the progression-free survival time